PET-basierte Bestrahlungsplanung

Michael Grunert; Vikas Prasad

doi:10.1055/a-1218-5129

Radiopraxis, Table of Contents

Radiopraxis 2020; 13(04): E80-E97
DOI: 10.1055/a-1218-5129

CPD–Fortbildung

PET-basierte Bestrahlungsplanung

PET based radiation planning

Michael Grunert

,

Vikas Prasad

Abstract

Die Strahlentherapie ist fest in der Behandlung von Kopf-Hals-Tumoren verankert, und die [¹⁸F]-FDG-PET hat als PET / CT und PET / MRT einen zunehmenden Stellenwert in der personalisierten Therapie bei Kopf-Hals-Tumoren. Der Beitrag thematisiert die elementare Bedeutung einer Erfassung der genauen Tumorausdehnung und der daraus resultierenden Bestimmung der Tumorvolumina in der bildbasierten Strahlentherapieplanung als Grundlage für die erfolgreiche Bestrahlung.

Schlüsselwörter

PET / CT - Bestrahlungsplanung - IMRT - Strahlentherapie - Kopf-Hals-Tumoren

Full Text

References

Literatur
1 Stromberger C. Primäre und adjuvante Radio(chemo)therapie bei Kopf-Hals-Tumoren. Onkologe 2019; 25: 240-245
2 Rasch C, Steenbakkers R, van Herk M. Target definition in prostate, head, and neck. Semin Radiat Oncol 2005; 15: 136-145
3 Ligtenberg H, Jager EA, Caldas-Magalhaes J. et al. Modalityspecific target definition for laryngeal and hypopharyngeal cancer on FDG-PET, CT and MRI. Radiother Oncol 2017; 123: 63-70
4 Cacicedo J, Navarro A, Del Hoyo O. et al. Role of fluorine-18 fluorodeoxyglucose PET / CT in head and neck oncology: the point of view of the radiation oncologist. Br J Radiol 2016; 89: 20160217
5 Daisne JF, Duprez T, Weynand B. et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 2004; 233: 93-100
6 Anderson CM, Sun W, Buatti JM. et al. Interobserver and intermodality variability in GTV delineation on simulation CT, FDG-PET, and MR Images of Head and Neck Cancer. Jacobs J Radiat Oncol 2014; 1: 006
7 Rusthoven KE, Koshy M, Paulino AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer 2004; 101: 2641-2649
8 Zhu L, Wang N. ¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography as a diagnostic tool in patients with cervical nodal metastases of unknown primary site: a meta-analysis. Surg Oncol 2013; 22: 190-194
9 Büther F. Von PET und PET / CT zur PET / MRT: Ein technologisches Update. Nuklearmediziner 2018; 41: 202-210
10 Geets X, Lee JA, Bol A. et al. A gradient-based method for segmenting FDG-PET images: methodology and validation.. Eur J Nucl Med Mol Imaging 2007; 34: 1427-1438
11 Purandare NC, Agrawal A, Shah S. et al. ¹⁸F FDG PET / CT: Normal variants, artefacts and pitfalls in head and neck malignancy. In: Wong WL eds. PET / CT in head and neck cancer. Berlin: Springer; 2018: 29-42
12 Krause BJ, Beyer T, Bockisch A. et al. FDG-PET / CT in der Onkologie. Leitlinie der Deutschen Gesellschaft für Nuklearmedizin e. V. DGN. Nuklearmedizin 2007; 46: 291-301
13 Fukui MB, Blodgett TM, Snyderman CH. et al. Combined PETCT in the head and neck: part 2. Diagnostic uses and pitfalls of oncologic imaging. Radiographics 2005; 25: 913-930
14 Jeong J, Setton JS, Lee NY. et al. Estimate of the impact of FDG-avidity on the dose required for head and neck radiotherapy local control. Radiother Oncol 2014; 111: 340-347
15 Madani I, Duthoy W, Derie C. et al. Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 68: 126-135
16 Henriques de Figueiredo B, Zacharatou C, Galland-Girodet S. et al. Hypoxia imaging with [18F]-FMISO-PET for guided dose escalation with intensity-modulated radiotherapy in headand-neck cancers. Strahlenther Onkol 2015; 191: 217-224
17 Monnich D, Thorwarth D, Leibfarth S. et al. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer. Acta Oncol 2017; 56: 1577-1582
18 Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007; 25: 4066-4074
19 Xu Z, Li XF, Zou H. et al. (18)F-Fluoromisonidazole in tumor hypoxia imaging. Oncotarget 2017; 8: 94969-94979
20 Henriques de Figueiredo B, Merlin T, de Clermont-Gallerande H et al. Potential of [¹⁸F]-fluoromisonidazole positronemission tomography for radiotherapy planning in head and neck squamous cell carcinomas. Strahlenther Onkol 2013; 189: 1015-1019
21 Eschmann S, Paulsen F. Bedeutung der Hypoxiebildgebung mit PET für die Bestrahlungsplanung. Nuklearmediziner 2008; 31: 33-36
22 Chang JH, Wada M, Anderson NJ. et al. Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: a biological modeling study. Acta Oncol 2013; 52: 1723-1729
23 Lock S, Perrin R, Seidlitz A. et al. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging. Radiother Oncol 2017; 124: 533-540
24 Carlin S, Humm JL. PET of hypoxia: current and future perspectives. J Nucl Med 2012; 53: 1171-1174
25 Watanabe S, Shiga T, Hirata K. et al. Biodistribution and radiation dosimetry of the novel hypoxia PET probe [(18)F] DiFA and comparison with [(18)F]FMISO. EJNMMI Res 2019; 9: 60
26 Hoeben BA, Troost EG, Span PN. et al. ¹⁸F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. J Nucl Med 2013; 54: 532-540
27 Szyszko TA, Cook GJR. PET / CT and PET / MRI in head and neck malignancy. Clin Radiol 2018; 73: 60-69
28 Samolyk-Kogaczewska N, Sierko E, Zuzda K. et al. PET / MRIguided GTV delineation during radiotherapy planning in patients with squamous cell carcinoma of the tongue. Strahlenther Onkol 2019
29 Wang K, Mullins BT, Falchook AD. et al. Evaluation of PET / MRI for tumor volume delineation for head and neck cancer. Front Oncol 2017; 7: 8
30 Becker M, Varoquaux AD, Combescure C. et al. Local recurrence of squamous cell carcinoma of the head and neck after radio(chemo)therapy: Diagnostic performance of FDGPET / MRI with diffusion-weighted sequences. Eur Radiol 2018; 28: 651-663
31 Stumpp P, Purz S, Sabri O. et al. [Molecular imaging of head and neck cancers: Perspectives of PET / MRI]. Radiologe 2016; 56: 588-596
32 Bailey DL, Pichler BJ, Guckel B. et al. Combined PET / MRI: from status quo to status go. Summary report of the Fifth International Workshop on PET / MR Imaging. February 15-19, 2016; Tubingen, Germany. Mol Imaging Biol 2016; 18: 637-650
33 Lagendijk JJ, Raaymakers BW. Van den Berg CA et al. MR guidance in radiotherapy. Phys Med Biol 2014; 59: R349-369
34 Winter RM, Leibfarth S, Schmidt H. et al. Assessment of image quality of a radiotherapy-specific hardware solution for PET / MRI in head and neck cancer patients. Radiother Oncol 2018; 128: 485-491
35 Rai R, Kumar S, Batumalai V. et al. The integration of MRI in radiation therapy: collaboration of radiographers and radiation therapists. J Med Radiat Sci 2017; 64: 61-68
36 Kao J, Vu HL, Genden EM. et al. The diagnostic and prognostic utility of positron emission tomography / computed tomography-based follow-up after radiotherapy for head and neck cancer. Cancer 2009; 115: 4586-4594
37 Gupta T, Master Z, Kannan S. et al. Diagnostic performance of post-treatment FDG PET or FDG PET / CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2011; 38: 2083-2095
38 Mehanna H, Wong WL, McConkey CC. et al. PET-CT Surveillance versus neck dissection in advanced head and neck cancer. N Engl J Med 2016; 374: 1444-1454
39 coll Tragende Gründe zum Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Richtlinie Methoden vertragsärztliche Versorgung: Positronenemissionstomographie (PET) PET / Computertomographie (CT) bei Kopf-Hals-Tumoren (Juni 2017). Im Internet: (Stand: 27. 12.2019) http://www.g-ba.de/downloads/40-268-4266/2017-03-16_MVV-RL_PETCT-Kopf-Hals-Tumoren_TrG.pdf
40 Ong SC, Schoder H, Lee NY. et al. Clinical utility of ¹⁸F-FDG PET / CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer. J Nucl Med 2008; 49: 532-540
41 Leung AS, Rath TJ, Hughes MA. et al. Optimal timing of first posttreatment FDG PET / CT in head and neck squamous cell carcinoma. Head Neck 2016; 38 (Suppl. 01): E853-858
42 Helsen N, Roothans D, Van Den Heuvel B. et al. ¹⁸F-FDG-PET / CT for the detection of disease in patients with head and neck cancer treated with radiotherapy. PLoS One 2017; 12: e0182350
43 Sheikhbahaei S, Ahn SJ, Moriarty E. et al. Intratherapy or posttherapy FDG PET or FDG PET / CT for patients with head and neck cancer: a systematic review and meta-analysis of prognostic studies. Am J Roentgenol 2015; 205: 1102-1113
44 Beswick DM, Gooding WE, Johnson JT. et al. Temporal patterns of head and neck squamous cell carcinoma recurrence with positron-emission tomography / computed tomography monitoring. Laryngoscope 2012; 122: 1512-1517
45 Smith AF, Hall PS, Hulme CT. et al. Cost-effectiveness analysis of PET-CT-guided management for locally advanced head and neck cancer. Eur J Cancer 2017; 85: 6-14
46 Castelli J, De Bari B, Depeursinge A. et al. Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy. Crit Rev Oncol Hematol 2016; 108: 40-51
47 Wang L, Bai J, Duan P. Prognostic value of ¹⁸F-FDG PET / CT functional parameters in patients with head and neck cancer: a meta-analysis. Nucl Med Commun 2019; 40: 361-369
48 Kim KR, Shim HJ, Hwang JE. et al. The role of interim FDG PET-CT after induction chemotherapy as a predictor of concurrent chemoradiotherapy efficacy and prognosis for head and neck cancer. Eur J Nucl Med Mol Imaging 2018; 45: 170-178
49 Wong KH, Panek R, Welsh L et al.. The predictive value of early assessment after 1 cycle of induction chemotherapy with ¹⁸F-FDG PET / CT and diffusion-weighted mri for response to radical chemoradiotherapy in head and neck squamous cell carcinoma. J Nucl Med 2016; 57: 1843-1850
50 Schinagl DA, Vogel WV, Hoffmann AL. et al. Comparison of five segmentation tools for ¹⁸F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 69: 1282-1289
51 Perez-Romasanta LA, Bellon-Guardia M, Torres-Donaire J. et al. Tumor volume delineation in head and neck cancer with 18-fluor-fluorodeoxiglucose positron emission tomography: adaptive thresholding method applied to primary tumors and metastatic lymph nodes. Clin Transl Oncol 2013; 15: 283-293
52 Leclerc M, Lartigau E, Lacornerie T. et al. Primary tumor delineation based on (18)FDG PET for locally advanced head and neck cancer treated by chemo-radiotherapy. Radiother Oncol 2015; 116: 87-93 : 10.1016 / j.radonc. 2015.06.007
53 Speer S, Klein A, Kober L. et al. Automation of radiation treatment planning: Evaluation of head and neck cancer patient plans created by the Pinnacle(3) scripting and Auto-Planning functions. Strahlenther Onkol 2017; 193: 656-665
54 Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology 2016; 278: 563-577
55 Deist TM, Dankers F, Valdes G. et al. Machine learning algorithms for outcome prediction in (chemo)radiotherapy: An empirical comparison of classifiers. Med Phys 2018; 45: 3449-3459
56 Cozzi L, Franzese C, Fogliata A. et al. Predicting survival and local control after radiochemotherapy in locally advanced head and neck cancer by means of computed tomography based radiomics. Strahlenther Onkol 2019
57 Castelli J, Depeursinge A, Devillers A. et al. PET-based prognostic survival model after radiotherapy for head and neck cancer. Eur J Nucl Med Mol Imaging 2019; 46: 638-649
58 Hatt M, Tixier F, Pierce L. et al. Characterization of PET / CT images using texture analysis: the past, the present … any future? Eur J Nucl Med Mol Imaging 2017; 44: 151-165